Friday, Oct 22, 1982
South San Francisco, Calif. -- October 22, 1982 --Genentech, Inc. , a leading gene-splicing company, today announced the election of two new members to its Board of Directors.
The new directors are Harry Faulkner, President and Chief Executive Officer of Alfa-Laval AB, of Sweden, and Dr. John T. Potts, Jr., Chief of the Department of Medicine of Massachusetts General Hospital and Jackson Professor of Clinical Medicine at Harvard University Medical School.
Mr. Faulkner joined Alfa-Laval in 1957 in development & sales and rose to President and CEO in 1980. He holds a degree in engineering from MIT. Alfa-Laval is an equipment supplier to the biotechnology industry. The Company manufactures and markets process equipment, including separation and filtration systems.
Dr. Potts is a graduate of the University of Pennsylvania Medical School. After an internal medicine residency at Massachusetts General Hospital, he joined the National Heart Institute at Bethesda, Maryland. He was head of the Section on Polypeptide Hormones there when he left in 1958 to head the Endocrine Unit at Massachusetts General. He was named to his present post in May 1981.
Robert Swanson, President of Genentech, said, "We are extremely pleased to have two men of such experience, each in his own field, join our Board. Mr. Falkner will bring the expertise of over twenty years experience in the process development field, an area whose importance has increased as products of our research are now in the manufacturing stage. Dr. Potts is well known for his work in advancing the understanding of the endocrine system. He has published extensively in the areas of calcium metabolism and the hormonal mechanisms that govern it. His work is now being extended into recombinant DNA techniques and we will also benefit from his knowledge in all areas of clinical medicine."
Genentech is in the business of research, development, manufacturing, and marketing of products of recombinant DNA technology for human health care, agricultural, and industrial chemical markets.
Genentech's headquarters are at 460 Point San Bruno Boulevard, South San Francisco, California 94080.
# # #